Q14. Which patient populations do you regard as most likely to benefit from the IDSA guidelines?
Summary: The IDSA guidelines will benefit all patients by providing therapy based on latest evidence. The latest guidelines provide improved identification of high-risk and low-risk patients using the Multinational Association for Supportive Care in Cancer (MASCC) assessment schedule. This allows physicians to give more targeted individualized therapy based on assessment of disease and improved risk stratification.